Referral Patterns for Patients with Nonalcoholic Fatty Liver Disease

The incidence of nonalcoholic fatty liver disease (NAFLD) is rapidly increasing. This study evaluates the referral pattern of patients with NAFLD. A cohort study evaluating all patients with NAFLD referred to a single Gastroenterology Department from January 2017 to June 2020. Electronic patient referral letters were reviewed, and patients with NAFLD were diagnosed using standardized tests as part of a prospective cohort study. Predictors of nonalcoholic steatohepatitis (NASH) with significant (≥F2) fibrosis were evaluated in logistic regression analyses. In total, 323 (18.6%) of 1735 patients referred to the Gastro Unit during the study period were diagnosed with NAFLD. Patients were referred from general practitioners (62.5%) or other hospital departments (37.5%). Most referral letters included information suggesting a possible diagnosis of NAFLD (patient history, blood tests, or diagnostic imaging) or used the nonspecific general diagnosis suspected disease (Z.038). Out of 110 patients referred for a liver biopsy, 71 (22%) had NASH with significant fibrosis (F2 n = 39, F3 n = 19, F4 n = 13). Thirty-nine of these patients were referred from the primary sector. A logistic regression analysis (adjusted for age and gender) including all 323 patients showed that type 2 diabetes was the only significant independent predictor of NASH with fibrosis.

[1]  K. Cusi,et al.  A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. , 2020, The New England journal of medicine.

[2]  J. Holst,et al.  Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis , 2020, Hepatology communications.

[3]  B. Nordestgaard,et al.  High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase–Lowering Effect of a HSD17B13 Variant , 2020, Hepatology.

[4]  G. Tarantino,et al.  Nonalcoholic Fatty Liver Disease: A Challenge from Mechanisms to Therapy , 2019, Journal of clinical medicine.

[5]  V. Wong,et al.  Reduced Patient-Reported Outcome Scores Associate with Level of Fibrosis in Patients with Nonalcoholic Steatohepatitis. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  C. Faselis,et al.  NAFLD-NASH: An Under-Recognized Epidemic. , 2017, Current vascular pharmacology.

[7]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[8]  R. Wong,et al.  Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross‐sectional analysis of 2011‐2014 National Health and Nutrition Examination Survey , 2017, Alimentary pharmacology & therapeutics.

[9]  S. Hunt,et al.  A disease‐specific quality of life instrument for non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis: CLDQ‐NAFLD , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[10]  T. Card,et al.  Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study , 2017, BMJ Open.

[11]  M. Kumar,et al.  Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. , 2017, Journal of hepatology.

[12]  E. Disse,et al.  EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral? , 2017, Diabetologia.

[13]  C. Day,et al.  Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance , 2016, British Medical Journal.

[14]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[15]  Z. Younossi,et al.  Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL) , 2016, Health and Quality of Life Outcomes.

[16]  T. Vilsbøll,et al.  Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia , 2016, Journal of internal medicine.

[17]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[18]  A. Sanyal,et al.  Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease , 2015, Seminars in Liver Disease.

[19]  D. S̆timac,et al.  Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. , 2014, World journal of gastroenterology.

[20]  Anne Tybjærg-Hansen,et al.  Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease , 2014, Nature Genetics.

[21]  Rachel M. Brown,et al.  Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial , 2013, BMJ Open.

[22]  Fabio Nascimbeni,et al.  From NAFLD in clinical practice to answers from guidelines. , 2013, Journal of hepatology.

[23]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[24]  N. Chalasani,et al.  Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.

[25]  R. Anty,et al.  Liver fibrogenesis and metabolic factors. , 2011, Clinics and research in hepatology and gastroenterology.

[26]  P. Schirmacher,et al.  Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease , 2011, Virchows Archiv.

[27]  K. Walsh,et al.  Adipokines in inflammation and metabolic disease , 2011, Nature Reviews Immunology.

[28]  H. Tilg,et al.  Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.

[29]  A. Kahraman,et al.  Obesity Affects the Liver – The Link between Adipocytes and Hepatocytes , 2010, Digestion.

[30]  B. Neuschwander‐Tetri,et al.  Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease , 2008, Gut.

[31]  Laura Herrero,et al.  Obesity, inflammation, and insulin resistance. , 2007, Gastroenterology.

[32]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[33]  A. McCullough,et al.  The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. , 2004, Clinics in liver disease.